MannKind(MNKD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - MannKind Corporation reported record quarterly revenue of $112 million in Q4 2025, representing a 46% increase from the prior year quarter [17] - For the full year 2025, total revenue was up 22% to $349 million, driven by growth in Afrezza and FUROSCIX [22] - GAAP net loss for Q4 2025 was $15.9 million, while non-GAAP adjusted net income was $1.5 million [23] - For the full year 2025, GAAP net income was $5.9 million, and non-GAAP adjusted net income was $59.5 million [23] Business Line Data and Key Metrics Changes - FUROSCIX generated net sales of $23.3 million in Q4 2025, up 91% year-over-year, and $70.4 million for the full year 2025 [7][22] - Afrezza generated $22.3 million in net US sales in Q4 2025, a 22% increase year-over-year, and $74.6 million in global net sales for the full year [10][22] - V-Go sales were $4 million for the quarter, a slight decline from the prior year [18] Market Data and Key Metrics Changes - The pediatric indication for Afrezza is expected to be a significant growth driver, with a PDUFA date of May 29, 2026 [7] - The FUROSCIX ReadyFlow Autoinjector has a PDUFA date of July 26, 2026, which is anticipated to expand the market opportunity [10] Company Strategy and Development Direction - MannKind's long-range plan is not dependent on future growth from United Therapeutics-related revenues, with expectations of over $350 million in royalties over the next 36 months [4] - The company aims to achieve a revenue run rate of over $450 million in 2026, supported by strategic investments in marketing and sales force expansion [6][25] - The acquisition of scPharmaceuticals is expected to strengthen MannKind's cardiometabolic franchise [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, highlighting a compound annual growth rate of approximately 46% over the past five years [5] - The company anticipates durable double-digit growth of Tyvaso DPI in 2026, which will positively impact royalty revenue [24] - Management emphasized the importance of the pediatric launch for Afrezza and the potential of the nintedanib DPI program in IPF [30] Other Important Information - The company has a long-term supply agreement with United Therapeutics that includes minimum orders expected to deliver over $400 million in revenue [4] - The recent FDA approval of a label change for Afrezza is expected to enhance its market position [12] Q&A Session Summary Question: How is the $350 million number over the next 36 months being considered? - Management clarified that the minimum supply agreement with United Therapeutics is volume-based and provides predictability for future revenues [35][36] Question: What is the strategic priority of the MNKD-201 program? - Management indicated that MNKD-201 is a critical priority, with significant resources allocated to its development and upcoming phase 1 and phase 2 trials [38][39] Question: Can the UT supply contracts be updated in future years? - Management stated that while the agreement includes minimum production, modifications could occur with mutual agreement [44][46] Question: What are the growth drivers for Afrezza and FUROSCIX? - Management highlighted the pediatric launch for Afrezza and the anticipated approval of the FUROSCIX auto-injector as key growth drivers [50][51] Question: How will gross margins evolve in 2026? - Management noted a slight decline in gross margins initially due to the auto-injector but expects significant improvement post-launch [56]